Post Resch Tallon Group Inc. Cardiff Oncology, Inc. Transaction History
Post Resch Tallon Group Inc.
- $118 Billion
- Q4 2025
A detailed history of Post Resch Tallon Group Inc. transactions in Cardiff Oncology, Inc. stock. As of the latest transaction made, Post Resch Tallon Group Inc. holds 22,503 shares of CRDF stock, worth $48,381. This represents 0.05% of its overall portfolio holdings.
Number of Shares
22,503
Previous 22,538
0.16%
Holding current value
$48,381
Previous $46.4 Million
36.2%
% of portfolio
0.05%
Previous 0.04%
Shares
2 transactions
Others Institutions Holding CRDF
# of Institutions
126Shares Held
21.9MCall Options Held
1.11MPut Options Held
150K-
Vanguard Group Inc Valley Forge, PA3.59MShares$7.72 Million0.0% of portfolio
-
Black Rock Inc. New York, NY2.63MShares$5.65 Million0.0% of portfolio
-
Laurion Capital Management LP New York, NY2.47MShares$5.3 Million0.09% of portfolio
-
Blair William & CO Chicago, IL2.21MShares$4.76 Million0.01% of portfolio
-
Acorn Capital Advisors, LLC New York, NY1.96MShares$4.22 Million2.05% of portfolio
About Cardiff Oncology, Inc.
- Ticker CRDF
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,334,900
- Market Cap $93.2M
- Description
- Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...